Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 8921–8925 | Cite as

Polymorphism in PHD1 gene and risk of non-small cell lung cancer in a Chinese population

  • Jianhua Che
  • Dong Jiang
  • Yabiao Zheng
  • Bin Zhu
  • Ping Zhang
  • Deyi Lu
  • Junjie Zhang
  • Juanjuan Xiao
  • Jianguo Wang
  • Yuzhen Gao
  • Xiaolong Yan
  • Minghua Wang
Research Article

Abstract

Hypoxia is a common phenomenon in the development of solid tumors, and hypoxia inducible factor 1 (HIF-1) plays a central role in coordinating the cellular response to hypoxia and in oxygen homeostasis. The prolyl hydrolase 1 (PHD1) is a key adjustment factor that mediates the HIF-1 degradation and relates with the process of tumorigenesis. Thus, polymorphism in PHD1 may affect cellular response to hypoxic conditions and associate with cancer susceptibility. We conducted a case–control study with 406 non-small cell lung cancer cases and 812 healthy controls matched on age and sex to examine the effect of rs10680577 polymorphism within the PHD1 promoter on non-small cell lung cancer (NSCLC) risk in a Chinese population. The genotype of rs10680577 polymorphism was detected by non-denaturing polyacrylamide gel electrophoresis. The ins/del genotype of rs10680577 was associated with significantly increased non-small cell lung cancer risk (ins/del vs. ins/ins: OR = 1.35, 95 % confidence interval (CI) 1.05–1.74, P = 0.020; ins/del vs. ins/ins + del/del: OR = 1.34, 95 % CI = 1.04–1.72, P = 0.022). In addition, the association was more pronounced in the group of >60 years of age. rs10680577 polymorphism is associated with the risk of non-small cell lung cancer in a Chinese population. This is the first time to show that PHD1 rs10680577 is associated NSCLC risk.

Keywords

PHD1 rs10680577 Non-small cell lung cancer Polymorphism 

Notes

Acknowledgments

This work was supported by the grants from the National Natural Science Foundation of China (grant numbers 81071957 and 81000938).

Conflicts of interest

None

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi: 10.3322/caac.20073.CrossRefPubMedGoogle Scholar
  3. 3.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. doi: 10.4065/83.5.584.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med. 2007;85(12):1301–7. doi: 10.1007/s00109-007-0281-3.CrossRefPubMedGoogle Scholar
  5. 5.
    Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE Signal Transduct Knowl Environ. 2007;2007(407):cm8. doi: 10.1126/stke.4072007cm8
  6. 6.
    Kaelin Jr WG. How oxygen makes its presence felt. Genes Dev. 2002;16(12):1441–5. doi: 10.1101/gad.1003602.CrossRefPubMedGoogle Scholar
  7. 7.
    Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp. 2006;272:15–25. Discussion −36.CrossRefPubMedGoogle Scholar
  8. 8.
    Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol. 2002;13(1):29–37. doi: 10.1006/scdb.2001.0287.CrossRefPubMedGoogle Scholar
  9. 9.
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279(37):38458–65. doi: 10.1074/jbc.M406026200.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen S, Zhang J, Li X, Luo X, Fang J, Chen H. The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem. 2011;358(1–2):257–63. doi: 10.1007/s11010-011-0976-1.CrossRefPubMedGoogle Scholar
  12. 12.
    Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, et al. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011;6(8):e23847. doi: 10.1371/journal.pone.0023847.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Zhu Z, Gao X, He Y, Zhao H, Yu Q, Jiang D, et al. An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk. Cancer Res. 2012;72(23):6163–72. doi: 10.1158/0008-5472.CAN-12-0010.CrossRefPubMedGoogle Scholar
  14. 14.
    Walsh PS, Metzger DA, Higushi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. BioTech. 2013;10(4):506–13. (April 1991). BioTechniques. 2013;54(3):134–9.Google Scholar
  15. 15.
    Allen RC, Graves G, Budowle B. Polymerase chain reaction amplification products separated on rehydratable polyacrylamide gels and stained with silver. BioTech. 1989;7(7):736–44.CrossRefGoogle Scholar
  16. 16.
    Chen S, He Y, Ding J, Jiang Y, Jia S, Xia W, et al. An insertion/deletion polymorphism in the 3' untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun. 2010;391(1):552–6. doi: 10.1016/j.bbrc.2009.11.096.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009;16(5):413–24. doi: 10.1016/j.ccr.2009.09.029.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2012;133(1):179–88. doi: 10.1007/s10549-011-1750-5.CrossRefPubMedGoogle Scholar
  19. 19.
    Kaufmann MR, Schraml P, Hermanns T, Wenger RH, Camenisch G. Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma. Exp Mol Pathol. 2013;94(3):453–7. doi: 10.1016/j.yexmp.2013.03.005.CrossRefPubMedGoogle Scholar
  20. 20.
    Yi Y, Mikhaylova O, Mamedova A, Bastola P, Biesiada J, Alshaikh E, et al. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(21):5142–52. doi: 10.1158/1078-0432.CCR-09-3416.CrossRefGoogle Scholar
  21. 21.
    Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN, et al. Expression of key hypoxia sensing prolyl-hydroxylases PHD1, −2 and −3 in pancreaticobiliary cancer. Histopathology. 2010;56(7):908–20. doi: 10.1111/j.1365-2559.2010.03566.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Halvorsen M, Martin JS, Broadaway S, Laederach A. Disease-associated mutations that alter the RNA structural ensemble. PLoS Genet. 2010;6(8):e1001074. doi: 10.1371/journal.pgen.1001074.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jianhua Che
    • 1
    • 2
  • Dong Jiang
    • 3
  • Yabiao Zheng
    • 1
  • Bin Zhu
    • 2
  • Ping Zhang
    • 1
  • Deyi Lu
    • 1
  • Junjie Zhang
    • 1
  • Juanjuan Xiao
    • 1
  • Jianguo Wang
    • 1
  • Yuzhen Gao
    • 4
  • Xiaolong Yan
    • 5
  • Minghua Wang
    • 1
  1. 1.Department of Biochemical and Molecular Biology, Medical CollegeSoochow UniversitySuzhouChina
  2. 2.Department of Medical Genetics, Medical CollegeSoochow UniversitySuzhouChina
  3. 3.Department of Cardio-Thoracic SurgeryThe First Affiliated Hospital of Soochow UniversitySuzhouChina
  4. 4.Department of Forensic Medicine, Medical CollegeSoochow UniversitySuzhouChina
  5. 5.Department of Thoracic Surgery, Tangdu HospitalFourth Military Medical UniversityXi’anChina

Personalised recommendations